UPDATE - UBS Initiates Coverage on MedAssets (MDAS) with a Neutral; Broadlane is a Game Changer
Tweet Send to a Friend
UPDATE - UBS initiates coverage on MedAssets (Nasdaq: MDAS) with a Neutral rating, price target $23.
UBS analyst says, "As ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
UBS analyst says, "As ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
